AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24713545
Drug: AEZS-108 (267mg/m²,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEZS-108 (267mg/m², equimolar to 76.8mg/m² of free doxorubicin) every 3 weeks as a two-hour i.v. infusion
Trial: 20151839
Drug: Maraviroc (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (300 mg once or twice daily) with zidovudine-lamivudine
Trial: 20151839
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg once daily) with zidovudine-lamivudine
Trial: 20151839
Drug: Maraviroc (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (300 mg once or twice daily)
Trial: 15896918
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dexamethasone suppression test (DST) in BPD patients with comorbid PTSD
Trial: 15896918
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dexamethasone suppression test (DST) in total BPD group
Trial: 15896918
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dexamethasone suppression test (DST) in healthy controls
Trial: 15896918
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dexamethasone suppression test (DST) in BPD patients without PTSD
Trial: 10066854
Drug: Additional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional treatment by a qualified physiotherapist
Trial: 10066854
Drug: Additional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional treatment by a physiotherapy assistant
Trial: 8828605
Drug: Dietary restriction
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary restriction of phenylalanine (continued therapy)
Trial: 8828605
Drug: Dietary restriction
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary restriction of phenylalanine (discontinued therapy)
Trial: 1564674
Drug: Future oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Future oriented hypnotic imagery presented as hypnosis
Trial: 1564674
Drug: Future oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Future oriented hypnotic imagery not presented as hypnosis
Trial: 3932499
Drug: 2% cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% cromolyn sodium (CS) ophthalmic solution, used six times daily for 5 weeks
Trial: 3932499
Drug: Placebo, used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, used six times daily for 5 weeks
Trial: 26414976
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for pain
Trial: 19813008
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg oral salmon calcitonin (sCT) at 08:00
Trial: 19813008
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg oral salmon calcitonin (sCT) at 17:00
Trial: 19813008
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg oral salmon calcitonin (sCT) at 22:00
Trial: 19813008
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 08:00
Trial: 19813008
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 17:00
Trial: 7749977
Drug: Ebastine 1
RxNorm normalized name: ebastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 1 mg
Trial: 7749977
Drug: Ebastine 3
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 3 mg
Trial: 1546142
Drug: moclobemide, 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide, 450 mg/j
Trial: 1546142
Drug: viloxazine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: viloxazine, 300 mg/j
Trial: 1546142
Drug: maprotiline, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maprotiline, 150 mg/j
Trial: 6375537
Drug: Propranolol (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (480 mg/day for 6 weeks)
Trial: 6375537
Drug: Verapamil (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (480 mg/day for 6 weeks)
Trial: 22332827
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine (NE) at 59 μmol/L
Trial: 22332827
Drug: Vasopressin (VP)
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin (VP) at 100 nmol/L
Trial: 20688574
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (2 mg folic acid, 25 mg vitamin B6, and 0.5 mg vitamin B12)
Trial: 18044297
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (bupivacaine 0.25% 6-10 ml + fentanyl 50-100 microg, followed by bupivacaine 0.125% + fentanyl 1-2 microg/ml at 6-12 ml/h)
Trial: 11816327
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA), initial dose of 10-15 mg/kg given 10-15 minutes before tourniquet release, with possible repeat doses every 6-8 hours during the first postoperative day.
Trial: 31162140
Drug: NT-proBNP predictive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP predictive ability among black individuals with obesity (BMI ≥ 30 kg/m2) or eGFR < 60 mL/min/1.73 m2
Trial: 28738079
Drug: Ozone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone (20 μg/ml)
Trial: 23835693
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (DCCT)
Trial: 23835693
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (DCCT)
Trial: 11339520
Drug: Oral suspension
RxNorm normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension of meloxicam 7.5 mg daily
Trial: 11339520
Drug: Solid formulation
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid formulation of meloxicam 15 mg
Trial: 9213408
Drug: Icelandic Moss
RxNorm normalized name: Oak moss
DrugBank: Evernia prunastri (DB14172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icelandic Moss (Cetraria islandica) lozenges, 0.48 g per day (10 lozenges per day)
Trial: 7864949
Drug: Albuterol delivered
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol delivered by metered-dose inhaler (MDI)
Trial: 3666666
Drug: pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pirenzepine 50 mg b.i.d.
Trial: 30224261
Drug: CHA2DS2‐VASc based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHA2DS2‐VASc based anticoagulant treatment recommendation
Trial: 20553856
Drug: Repeated antenatal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated antenatal corticosteroid treatment
Trial: 20553856
Drug: Single antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antenatal corticosteroid treatment
Trial: 12929196
Drug: Intramuscular caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular caffeine injection (0.5 ml, 20 mM)
Trial: 10812530
Drug: Pramipexole 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 1.0 mg per day
Trial: 10812530
Drug: Pramipexole 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 5.0 mg per day
Trial: 8692301
Drug: Endoscopic CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic CO2 laser vaporization treatment
Trial: 1519524
Drug: Angina-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angina-directed medical therapy
Trial: 1519524
Drug: Angina plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angina plus ambulatory electrocardiographic-directed medical therapy
Trial: 6234281
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg bd norfloxacin
Trial: 6234281
Drug: 160/800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/800 mg bd cotrimoxazole
Trial: 29633025
Drug: 200-μg vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-μg vaginal misoprostol, 3 hours prior to vaginoscopic hysteroscopy
Trial: 26541687
Drug: Antidepressants (sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (sertraline and mianserin)
Trial: 26541687
Drug: Flexible cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible cognitive-behavioural therapy (CBT)
Trial: 26541687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of psychotherapy and medicine
Trial: 19286598
Drug: Treatment arms
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arms from various clinical trials for acute stroke
Trial: 19286598
Drug: National Institute
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: National Institute of Neurological Diseases and Stroke intravenous recombinant tissue plasminogen activator trial
Trial: 19286598
Drug: Stroke‐Acute Ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke‐Acute Ischemic NXY Treatment and Abciximab Emergent Stroke Treatment Trial
Trial: 11879254
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg (intravenous)
Trial: 11879254
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg (oral) in fed state
Trial: 11879254
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg (oral) in fasted state
Trial: 11879254
Drug: Sildenafil doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil doses of 25, 50, 100, and 200 mg (oral)
Trial: 11879254
Drug: Sildenafil (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (various doses)
Trial: 7721431
Drug: Intralipid/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid/heparin
Trial: 7721431
Drug: saline/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline/heparin
Trial: 7721431
Drug: dextrose/heparin
RxNorm normalized name: DEXTROSE/HEPARIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextrose/heparin
Trial: 1645503
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral therapy with azithromycin
Trial: 1645503
Drug: Standard 7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 7-day twice-daily course of doxycycline
Trial: 31034640
Drug: 300 min/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 min/wk aerobic exercise (HIGH dose group)
Trial: 31034640
Drug: 150 min/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 min/wk aerobic exercise (MODERATE dose group)
Trial: 26930244
Drug: Medulla powder
RxNorm normalized name: Cyathea medullaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medulla powder (15 g/day)
Trial: 26930244
Drug: Whole fruit
RxNorm normalized name: Astragalus exscapus whole flowering-fruiting extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole fruit powder (15 g/day)
Trial: 17634728
Drug: Dentifrice containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 550 microg F/g, pH 5.5 (experimental)
Trial: 17634728
Drug: Dentifrice containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 1, 100 microg F/g, pH 7.0 (positive control)
Trial: 15070956
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (1.3 g, 57 mmol)
Trial: 15070956
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (4 g, 172 mmol)
Trial: 8064943
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine phosphate (5 mg base kg‐1)
Trial: 8064943
Drug: Placebo (multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (multivitamin tablet)
Trial: 1200338
Drug: Intramuscular chlorprothixene
RxNorm normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular chlorprothixene (1 mg/kg)
Trial: 1200338
Drug: Oral chlorprothixene
RxNorm normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chlorprothixene (4% solution, 1.5-2 mg/kg)
Trial: 1200338
Drug: Intramuscular 1-hyoscyamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 1-hyoscyamine (0.005-0.01 mg/kg)
Trial: 26001837
Drug: Cardiac output-guided
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac output-guided haemodynamic therapy
Trial: 10661690
Drug: Alcohol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (75 ml)
Trial: 9403805
Drug: TRH injection
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRH injection (0.2 mg protirelin, iv)
Trial: 9403805
Drug: Atropine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1 mg, iv)
Trial: 26242177
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of rocuronium 0.6 mg/kg per hour
Trial: 26242177
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of NaCl 0.9 % 0.06 ml/kg per hour
Trial: 23954097
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1,000 mg as elemental calcium) with vitamin D‐3 (400 IU) daily
Trial: 20948291
Drug: Muromonab CD3
RxNorm normalized name: Muromonab-Cd3
DrugBank: Muromonab (DB00075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Muromonab CD3 (monoclonal antibody targeting CD3)
Trial: 20948291
Drug: Novel monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel monoclonal antibodies targeting co‐stimulatory signals, cell surface receptors, and novel protein constructs
Trial: 12727577
Drug: Aggressive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lipid-lowering strategy involving up to 80 mg/d of atorvastatin with a target LDL cholesterol level <77 mg/dL
Trial: 12727577
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy of lipids with LDL cholesterol target level <116 mg/dL
Trial: 8222384
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg SIN-1 administered via intracoronary route
Trial: 8222384
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg SIN-1 administered via intravenous route
Trial: 3899346
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with previous treatment
Trial: 3899346
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with no previous treatment
Trial: 24851997
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion to maintain platelet counts at or above 50 × 10(9)/l
Trial: 24851997
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion to maintain platelet counts at or above 25 × 10(9)/l
Trial: 9390111
Drug: SDZ HTF
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ HTF 919 25 mg
Trial: 9390111
Drug: SDZ HTF
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ HTF 919 100 mg
Trial: 9390111
Drug: SDZ HTF
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ HTF 919 1 mg
Trial: 9390111
Drug: SDZ HTF
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ HTF 919 5 mg
Trial: 7962372
Drug: Classical vaporization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical vaporization of the ovarian capsule (22 women)
Trial: 7962372
Drug: Simple perforation
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple perforation of the ovarian capsule with subcapsular destruction of the ovarian stroma (22 women)
Trial: 7962372
Drug: Overall conception
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall conception rate after laparoscopic argon laser treatment
Trial: 7962372
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate therapy post-operatively
Trial: 28642082
Drug: 50,000IU vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000IU vitamin D supplements
Trial: 17033039
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2
Trial: 14585088
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program (8 weeks of supervised endurance exercise, 75% VO(2peak), 45 min twice a week, with intermittent exercise once a week)
Trial: 10922194
Drug: Oral acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acyclovir, 800 mg/d
Trial: 30803168
Drug: Intestinal preparation
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intestinal preparation with polyethylene glycol
Trial: 30803168
Drug: Non intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non intestinal preparation
Trial: 21939591
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy for psychosis (CBT-P)
Trial: 19584345
Drug: 2-dose PCV-7
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-dose PCV-7 schedule (2 and 4 months)
Trial: 19584345
Drug: 2 +
RxNorm normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 + 1-dose PCV-7 schedule (2, 4, and 11 months)
Trial: 19584345
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dosage)
Trial: 19584345
Drug: 2 +
RxNorm normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 + 1-dose PCV-7 schedule
Trial: 19584345
Drug: 2-dose PCV-7
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-dose PCV-7 schedule
Trial: 18240275
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg antofloxacin hydrochloride
Trial: 18240275
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg antofloxacin hydrochloride
Trial: 18240275
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg antofloxacin hydrochloride
Trial: 14562857
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug regimens containing Nevirapine
Trial: 8899318
Drug: Ukrain treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain treatment in preoperative phase
Trial: 8899318
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Ukrain treatment)
Trial: 1844999
Drug: Polylactate (PL:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polylactate (PL: 80% polylactate, 20% sodium lactate, in 7% solution with water)